Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab

[1]  B. Cheson,et al.  Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  L. Kanz,et al.  CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB , 1999, British journal of haematology.

[3]  M. Czuczman,et al.  Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  D. Maloney,et al.  Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Lister,et al.  Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma. , 1999, Blood.

[6]  D. Czerwinski,et al.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  T. Kinoshita,et al.  CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[9]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Narabayashi,et al.  Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  J Hermans,et al.  International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. , 1995, Blood.

[12]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[13]  A. López-Guillermo,et al.  Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[15]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[16]  Y. Shimada,et al.  Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.

[17]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[18]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[19]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[20]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Coiffier,et al.  Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  K. Tobinai.  Phase II study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed indolent B-cell lymphoma , 1999 .

[23]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[24]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.